• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Bicyclic fused benzenoid compounds of the formula and pharmaceutically acceptable cationic and acid addition salts thereof, where M is O, CH2 or NR6; R6 is hydrogen, formyl, carbobenzyloxy or certain carboalkoxyalkyl, alkanoyl, alkyl, aralkyl or aralkylcarbonyl groups; A' is: (1) A where one of A and B is hydrogen such that when A is hydrogen, B is C(R2R3) (CH2)fO and f is 1 or 2; when B is hydrogen, A is C(R2R3)(CH2)fO and f is 0 or 1, when taken together A and OR1 form a lactone or certain derivatives thereof; (2) A' is HOCH2CONR12R13; (3) A' is 03; O is CO2R7, CORe, C(OH)R8R9, CN, CONR12R13, CH2NR12R13, CH2NHCOR14, CH2NHSO2R17 or 5-tatrazoyl; 03 is spiro - 5-tetrazolyl, CH2CONHCOR7, COOH or certain ester, amide, carboximido or sulfonimido derivatives thereof, CONHOH, CONHCONH2, or COCH2O4 where O4 is CN or COOH or certain esters thereof; R1 is hydrogen, benzyl or certain acyl groups; R4 is hydrogen, certain alkyl or certain aralkyl groups; R5 is hydrogen or certain alkyl groups; Z is (C1-C9)alkylene, optionally interrupted by O, S, SO or S02; and W is hydrogen, methyl, certain aryl or cycloalkyl groups; useful in mammals as analgesics, tranquilizers, antiemetic agents, diuretics, anticonvulsants, antidiarrheals, antitussives, in treatment of glaucoma, and intermediates therefore.
    公开号:SU1316563A3
    申请号:SU833568915
    申请日:1983-03-15
    公开日:1987-06-07
    发明作者:Фредерик Егглер Джеймс；Росс Джонсон Майкл；Шерман Мелвин Лоренс (младший)
    申请人:Пфайзер Инк (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to the production of new bicyclic benzo-condensed compounds that have an analgesic effect and can be used as a remedy for diarrhea and as agents for treating and preventing imesis and nausea, especially when administering anti-neoplasia drugs.
    The aim of the invention is to obtain new compounds, derivatives of benzopyran or tetralin, with valuable biologically active properties.
    Example I. 4-H-Acetylcarbox-imido-5-hydroxy-2,2-dimethyl-7- (1,1-dimethylheptyl) -3,4-dihydro-N-benzopyran.
    A. p-Nitrophenyl-5-benzsh1oxy-2,2-dimethyl-7- (1,1-dimesh1heptyl) -3,4-dihydro-2H-benzopyran-4-carboxylate.
    A mixture of 3.3 g (mmol) of 5-benzyl, 2-dimethyl-7- (1, I-dimethylheptyl) -3,4-dihydro-2H-benzopyran-4-carboxylic acid, 5.0 g (21 , 3 mmol of p-nitrophenyl trifluoroacetate and 100 ml of dry pyridine are stirred under nitrogen at room temperature for three hours. Pyridine is evaporated under vacuum, ethyl ether is added to the residue and all is washed with 1N sodium hydroxide, water, 10% - hydrochloric acid, brine, dried MgS04H solvent vyparivayut to obtain 4.5 g of crude oil. This oil is taken in pentane and cooled to obtain 3.38 g of crystals, so pl. 87 -87 ,.
    B. 4-H-Atstsh1carboksimido-5-benzsh10ksi-2,2-dimethyl-7- (1,1-dimethyl-heptyl) -3,4-dihydro-2H-benzopyran.
    To 301 mg (5.1 mmol) of acetamide was added 35 ml of dry tetrahydrof CH (CH,). J C (CH,),
    during the addition of 103 mg of sodium hydride (99%) (4.3 mmol). The resulting mixture was stirred overnight under a nitrogen atmosphere, 400 mg (0.716 mmol) of p-nitrophenyl ether prepared in Part A was added, and stirring was continued at room temperature for one hour. The mixture was poured into ice-water, acidified to pH 3 with 10% hydrochloric acid and extracted with ethyl acetate. The extract is washed with brine, saturated sodium bicarbonate solution, again with brine, and dried with MgSO4. Evaporation of the solvent yields 416 m of a crude solid. The crude material is taken up in methylene chloride, washed with sodium bicarbonate solution, brine, dried (MgSO4) and the solvent is evaporated, yielding 331 mg of foam. Upon addition of hexane, 249 mg of crystals precipitated. Processing them with hot hexane gives 216 mg during cooling and filtration, so pl. 157-158 C.
    H-NMR (OOS1,) -, ppm, 8: 2.20 (s, 3N), 3.80 (t, W), 5.0 (s, 2H), 6.50 (s, 2H ), 7.30 (s, 5H), 8.10 (s, 1H).
    P. 21.6 mg of part B product, 45 mg of 5% palladium on carbon and 25 ml of ethyl acetate are shaken under a hydrogen atmosphere at atmospheric pressure for 2.5 hours. By filtration and evaporation of the filtrate, 158 mg of product are obtained, m.p. . 146-147 C.
    Repeating the procedure of part B with the corresponding amide of the formula R ,,, CONH, sulfonamide of the formula R, j, S02NH2 or urea instead of acetamide and by hydrogenating the resulting product using the method described in part C, the following imido compounds of the formula I are obtained, where Q is CONHCOR, , CONHSOjR or
    T. pl. 143-148 С
    Mass spectrum, m / e: M 431, base 360
     n-NMR (CDCl1), ppm, &: 4.05 (t, 1H), 6.50 (ri, 2H), 7.1 (s, 1H)
    Se
    CJ1, CH (CH,) (diastereomer A))
    Cj, HyCH (CH,) (diastereomer B)
    cn nn
    ,
    Q, CONHCONH-i
     CONHSOjR, where R ,, is CH,
    Q-J V V MllCiy-J-Xpy,
    Example 2. 5-hydroxy-2,2-dimethyl-7- (1,1-dimethylheptyl) -3,4-dihydro-2H-binzopyran-4-hydroxamic acid.
    A. A mixture of 5.0 g of 5-benzyloxy-2,2-dimethyl-7- (1,1-dimethylheptyl) -3,4-dihydro-2H-benzopyran-4-carboxylic acid, 500 mg of 5% catalyst - palladium on carbon and I50 ml of ethyl acetate are hydrogenated for three hours at a pressure of three atmospheres. After removing the catalyst and thinning the solvent, 4.25 g of foam is obtained. Purification by chromatography on silica gel, eluting with 2: 1 hexane / ethyl ether, affords 1.84 of product, m.p. 147-148 C.
    B. p-Nitrophenyl-5-hydroxy-2,2-dimethyl-7- (1,1-dimethyl-1-1) -3,4-dihydro-2H-benzopyran-4-carboxylate.
    A mixture of 4.25 g (12.3 mmol) of Part A, 8.67 g (37 mmol) of p-nitrophenyl trifluoroacetate and 50 ml of dry pyridine is stirred for 65 hours at room temperature. A mixture of you13165634
    M.p. 172-173 seconds
    M.p. 141-146 ° С
    Mass spectrum, m / e: M 479
    H-NMR (CDCl,), ppm: 3.85 (t, 1H), 4.3 (q, 1H), 6.2 (m, 2H), 7.2 (s, 5H)
    M.p. 144-149 ° C
    Mass spectrum: m / e: M 479 base 105
    H-NMR (CDCl1), h / mpn, K: 3.90 (t, W), 4.40 (k, 1H), 6.35 (m, 2H), 7.25 (s, 5H)
    M.p. 154-158 seconds
    Mass spectrum, m / e: M 390 (M-NH) 373
    M.p. 155-156 seconds
    Mass spectrum, m / e: M 425, base 303
    five
    0
    five
    Q

    Steam to remove the pyridine, and the residue is treated as described in Example 1A, to give 5.085 g (88%) of the desired ester. n-NMR (CDC1,), ppm, 6.5 (m, 2H), 6.7 (s, OH), 7.03-7.3 (m, 2H), 8.0 8.3 (m, 2H).
    C. A mixture of 43 mg (1.066 mmol) of powdered sodium hydroxide in 10 ml of pyridium under a nitrogen atmosphere is stirred and heated to dissolve, then cooled to 0 ° C, 111 mg (1.6 mmol) of hydroxylamine hydrochloride are added and stirred 15 minutes. A solution of 250 mg (0.533 mmol) of part B product in 3.0 ml of pyridine is added, the mixture is allowed to warm to room temperature, leaving it to stir overnight. Pyridine is evaporated, the residue is taken up in water and extracted with ethyl acetate. The combined extracts are washed with water, saturated brine and dried with MgSO4. Evaporation of the solvent allows
    five
    Lighten 260 mg of the crude product, which is loaded onto a column with 30 g of silica gel. Elution with 1: 1 hexane / ethanol for 10 fractions, followed by ethyl acetate to elute the desired product. Evaporation of the solvent (fractions 18-20) provided 158 mg of the title compound.
    Mass spectrum (). n-NMR (CDClI,), ppm, 8: 6.20 (4H, 2 aromatic, NH, OH), 10.0 (H, exchanges with DjO).
    . Example 3. H-2-Pyridyl-5-ox-2,2-dimethyl-7- (1,1-dimethylsteptyl) -3,4-dihydro-2H-benzopyrancarboxamide.
    A.K-2-Pyridyl-5-benzyloxy-2,2-dimethyl-7- (1,1-dimethylheptyl) -3,4-dihydro-2H-benzopyrancarboxamide.
    A mixture of 1.118 g (2.0 mmol) of 4-nitrophensh1-5-benzyloxy-2,2-dimethyl-7- (1,2-dimethylheptyl) -3,4-dihydro-2H- b.nzopyrancarboxylate, 376 mg ( 4.0 mmol) of 2-aminopyridine and 4 ml of pyridine are placed in a sealed tube and heated for 18 hours at 155-157 ° C. After cooling, the tube is opened, the mixture is concentrated to dryness under vacuum, the residue is dissolved in ethyl ether, washed with 1N. hydrochloric acid (25 ml), 1 n. sodium hydroxide (3 x 25 ml), water (2 x 25 ml) and brine (25 ml), the washed ethereal solution is dried (MgSO4), the solvent is added until 966 mg of oil is obtained. The oil is purified by chromatography on a silica gel column, eluting with hexane / methylene chloride (1: 4), then with 15% -Hbw ethyl ether in methylene chloride. The fractions containing the product are combined and the solvent is evaporated under vacuum to obtain 823 mg (80%) of the desired amine. F
    B. A mixture of 691 mg of each mentioned amide and 10% Pd / C catalyst, 1.08 g of 1,4-cyclohexadiene and 25 ml of dry ethanol is hydrogenated according to the procedure of Example 2. After removing the solvent under vacuum, 680 mg of crude debenzylated product are obtained. . This product is purified by column chromatography on silica gel, eluting with methylene chloride and then with methylene chloride containing 10% ethyl ether, finally, one ester to obtain 515 mg (90%) of de-benzylated material, which crystallizes from ethyl acetate / hexane
    Sana, providing a yield of 398 mg (70%) of the product, so pl. 166-167 seconds; mass
    spectrum, m / e; 424 (molecular ion), 119 base.
    5 C. Using a suitable amine ArNH instead of 2-pyridylamine, the compounds shown in Table 2 are obtained using the above procedure. one.
    Table 1
    15
    .
    238.5-239 M 430
    base
    Example 4. 4-Nitrophenyl-5benzyloxy-2, 2-dimethyl-7- (2-methylpropyl) -3,4-dihydro-2H-benzopyran-4carboxylate.
    A. 5-Benzyloxy-2,2-dimethyl-7- (2-mea ropyl) -3,4-dihydro benzene opiran-4-carboxylic acid.
    A mixture of 7.8 g (22.2 mmol) of 5-benzyl-hydroxy-4-cyano-2,2-dimesh1-7 (2-methylpropyl) -3,4-dihydro-2H-benzopyra, 12.5 g of KOH tablets and 200 ml of ethylene glycol is heated in nitrogen with a vertical cooler for 18 hours and cooled to ambient temperature. The mixture is acidified to pH 3 with concentrated hydrochloric acid, extracted with ethyl acetate, and the extracts are dried with MgSO4. Evaporation of solvent gives an oil, which is
    ut in ethyl ether, rinse with boi, brine, dried with MgSO4, and the solvent is evaporated, providing 8.25 g of the crude product as an acid, which is purified by chromatography on silica gel, eluting with ethyl ether / methylene chloride in a 1: 4 ratio, simply ether and finally methanol / ethyl ether in a ratio of 1: 9, to obtain 6.13 g of yield, which gives crystals of methylene chloride / hexane, m.p. 152-158 ° C.
    B. A mixture of 3.0 g (8.15 mmol) of the acid obtained in Part A, 2.87 g (12.2 mol) of p-nitrophenyl trifluoroacetate and 40 ml of dry pyridine is stirred at room temperature for 60 hours. Pyridine is evaporated. Under vacuum, the residue is washed with 1N. hydrochloric acid (3 X 25 ml), 1 n. sodium hydroxide (4 x 25 ml), water, brine, and dried with MgSO4. Evaporation of the solvent provides 4.0 g of the crude product as a foam, which crystallizes from methylene chloride / hexane to obtain 3.67 g of the title compound, m.p. . 125-126 ° C.
    Example 5. 5-hydroxy-2,2-dimethyl-7- (2-methylpropyl) -3,4-dihydro-2H-benzopyran-4-carboxylic acid, mp 185-187 ° C.
    The catalytic hydrogenation of the corresponding 5-benzyl ester is obtained using the methods described.
    Example 6 A. Using the methods of Examples 1 and 3, but starting from the p-nitrophenyl ester obtained in Example 4 and the appropriate amide or urea, the following compounds are obtained in the same way:
    Q OH
    M.p.
    CONHCOCsHj. SOSH-Tetrazol-5-yl
    CONHCOC (CHj), CONHCOCHjCHCCH,) 10. CONHSO, jCH (CHj) 2
    CONHSO C H
    Example 7. A. Using 3,3-dimethyl-6- (5-phenyl-2-pentyloxy) -8-benzyloxy-1-tetralone (obtained in US Pat. No. 4,188,495), a quantitative yield of the corresponding non-significant nitrile is obtained. 8-benzyloxy-1-cyano-3, 3-dimethyl-6 (5-phenyl-2-pentyloxy) -3,4-dihydronaphthalene as an orange oil.
    B. The oil obtained in part A is hydrogenated according to the procedure of Example 1C to obtain the corresponding tetralin-8-benzyloxy-1-cyano-3,3-dimethyl-6- (5-phenyl-2-pentoxy) tetralin with 89% output in the form of orange oil.
    0
    five
    0
    five
    0
    five
    C. Tetralninnitrile is hydrolyzed in ethylene glycol with potassium hydroxide using the procedure of Example 4A to give the corresponding acid, 8-benzyloxy-3,3-rimethyl-6- (5-phenyl-2-pentyloxy) -tralin-1-carboxylic acid, as a white foam with 39% yield.
    D. A mixture of 1.6 g of the product of Part C, 20 ml of methanol and 320 mg of 5% palladium on carbon (catalyst) is hydrogenated at a pressure of three atmospheres for three hours and the product is filtered through and evaporated the filtrate. 1.2 g of a colorless solid foam are obtained, which is 92.5% pure mixture of diastereomers according to the HPLC analysis on a Zobax Sil column and registered trademark E. I du Pont de Nemours and Co. I nc. Wilmington Del), 2% isopropyl alcohol in hexane at 1 ml / min.,
     n-NMR (CDCl,), h / mn &: 0.8 (s, 3N), 1.0 (s, 3N), 1.2 (d, 4H), 1.74 (m, 6H) , 2.5 (m, 4H) 3.7 (m, 1H), 4.16 (m, 1H), 6.1 (s, 2H), 7.1 (s, 3N), 8.1 (wide C., 1H), which is consistent with the structure for 8-hydroxy-3,3-dimethyl-6- (5-phenyl-2-pentoxy) -tetramyl-1-carboxylic acid.
    E, The reaction of the aforementioned acid (3.14 mmol) with p-nitrophenyl trifluoroacetate (3.45 mmol) in pyridine by the method of Example 2B gives 1.1 g (69%) p-nitrophenyl-8-hydroxy-3, 3- dimethyl-6- (5-phenyl-2-pentiloxy) tetralin-1-car bauxilate as a yellow oil.
    F. Using benzyl ether, obtained in part C, according to the method of part
    E, p-nitrophensh1-8 benzyloxy-3,37Dimethyl-6- (5-phenyl-2-pentyloxy) -tetralin-1-carboxylate can be obtained in the form of an oil in a yield of 90%. TLC: R 0.68 with hexane / ethyl acetate, 2: 1 (dissolver).
    And p and me R 8. 8-hydroxy-3, 3-dimethyl-6- (5-phenyl-2-pentyloxy tetralin 1-carboxamide.
    A.Reaction of 2.3 g (3.9 mmol) of p-nitrophenyl-8-benzyloxy-3, 3-dimethyl-6- (5-phenyl-2-pentoxy) and tetra-lin-l-carboxylate in excess liquid ammonia at -70 ° C for 30 min
    and evaporation of the excess ammonia gives a yellow paste which, on silica gel chromatography, eluted with a 1: 1 mixture of ethyl acetate / hexane, yields 730 mg of amide R 0.15 for those with a 2: 1 ethyl acetate-hexane / hexane solvent system . The starting material was also given (1.15 g).
    B. By hydrating the product of part A in 50 ml of methanol with 400 mg of 5% ka. Pd / C catalyst at a pressure of 3. atm for 4.5 h using conventional methods, a crude product can be obtained, which is purified by distillation. gel column using ethyl acetate / hexane (2: 1) as a solvent. 130 mg of the title compound are obtained as a white solid, m.p. 155-157 seconds
     H-NMR (CDCl,), ppm, G: 0.8 (s, ZN), 1.0 (s, ZN), 1.16 (d, ZN), 1.7 (m, 6H) 2.47 (m, 4H), 3.57 (m, 1H), 4.16 (m, 1H), 6.1 (d, 3N), 7.2
    (s, 5H).
    one
    C. Conduct a reaction of 0.55 g
    (1.1 mmol) p-nitrophenyl-8-hydroxy-3,3-dimesh-1-6- (5-fensh-1-2-pentyloxy) tetrapine-1-carboxylate in 10 ml of tetrahydrofuran with an excess of gaseous methylamine at room temperature the resulting mixture is poured into 10% hydrochloric acid, extracted with ethyl acetate. Using conventional methods, 0.50 g of N-methylamide - N-me-TIL-8-OXY-3, 3-dimethyl-6- (5-phenyl-2-pentyloxy) tetralin-I-carboxamide is obtained as a foam.
     H-NMR (CDC1,), ppm, b: 0.8 (s, ZN), 1.0 (s, ZN), 1.2 (d, 4H), 1.7 (m, 6H) , 2.53 (m, 6H), 3.6 (m, 1H), 4.23 (m, NH), 6.2 (d, 2H), 7.13 (s, 5H).
    Example 9. 8-Oxy-3, 3-dimethyl-6- (5-phenyl-2-pentyloxy) -tetralin-I-carbonyl urea.
    Using the reaction between 1.2 g (2 mmol) p-nitrophenyl-8-benzyloxy-3, 3-dimethyl-6- (5-fench1-2-pentyloxy) - tetrapin-1-carboxylate, 0.3 g (5 mmol) of urea and 0.248 g (10 mmol) of sodium hydride in 12 ml of dimethyl sulfoxide at room temperature for one hour isolated the product by the method of Example 1B. By removing the benzyl group by hydrogenation according to the procedure of Example 1C, a pure target compound can be obtained in 36% overall yield.
    H-NMR (CDCl), ppm, Y: 0.77 (s, 3N), 1.1 (m, 8H), 1.7 (m, 4H),
    2.5 (m, 4H), 3.6 (m, W), 4.16 (m, 1H), 5.7 (s, 1H), 6.1 (s, 2H), 7.1 (s, 5H ), 8.2 (s, 2H).
    Example 10. Reaction of 1.1 (1.9 mmol) p-nitrophenyl-8-hydroxy-3, 3-dimethyl-6- (5-phenyl-2-pentyloxy) tetralin-1-carboxylate, 1.0 g (17 mmol of acetamide, 361 mg (15 mmol) of sodium hydride in 70 ml of tetrahydrofuran according to the method of Example 1, part B and C, makes it possible to prepare 8-hydroxy-3,3-dimethyl-6- (5-phenyl-2-pentyloxy) -1-N-acetylcarboximide with 55% yield of the product as a foam.
     n-NMR (CDC1,), h / ml, 5: 0.7 (s, ZN), 1.0 (s, ZN), 1.16 (d, ZN),
    1.6 (m, 6H), 2.3 (s, 3N), 2.5 (m, 4H), 3.73 (m, 1H), 4.13 (m, 1H), 6.1 (s, 2H ), 7.1 (s, 5H), 8.5 (NH).
    I
    Example 11. 3-8-hydroxy-3, 3-dimethyl-6- (5-phenyl-2-pentyloxy) -tetralin-1 -yl-3-oxopropionitrile.
    To a solution of 2.4 ml of 2.1 M p-butyl lithium in 3.7 ml of tetrahydrofuran at -78 ° C is added a solution of 0.26 ml (5 mmol) of acetonitrile in 3.7 ml of THF, and the mixture is stirred for one hours at -78 s. A solution of 1.1 g (2.0 mmol) of p- "itropensh1-8 benzyloxy-3, 3-dimethyl-6- (5-fench1-2 pentyloxy) tetralin-1-carboxylate is added in
    3.7 ml of THF and continue to mix at -78 C for 30 minutes. The reaction mixture is warmed to room temperature, quenched with 7 ml of 10% hydrochloric acid and extracted with ethyl ether. The distribution of the product, as in the previous example, allows 1.13 g of crude benzyl ether to be obtained, which gives 500 mg of a purified intermediate product using silica gel chromatography: mass spectrum of molecular ion, 495.
    Removal of the benzyl group by hydrogenation according to the method of Example 1C affords the pure title compound.
     H-NMR (CDCl1), ppm, 8: 0.8 (s, 3N), 1.06 (s, 3N), 1.2 (m, 5H), 1.7 (m, 4H), 2.5 (m, 4H), 3.5 (s, 2H 4.0 (m, 2H), 6.1 (s, 2H), 7.1 (s, 5H).
    The analgesic properties of the proposed compounds are determined by experimentation using a thermal nociceptive agent, such as hitting the tail, or a chemical nociceptive agent, such as measuring the ability of the compound to suppress curl in the minor, caused by a phenylbenzoquinone stimulus.
    Experiments using thermal nociceptive pathogen.
    Experiments on anesthesia in mice using hot plates.
    The method used is modified. Controlled thermal excitation is applied to the paw by means of an aluminum plate with a thickness of 1/8. A 250 V infrared heat lamp reflector is placed under the bottom of the aluminum plate. A thermostat connected with thermistors on top of the plate, sets the program to the heating lamps in order to maintain the temperature constant (57 s). Each mouse descends into a glass cylinder (6 1/2 in diameter) located on the front plate, and the time begins when the animal's foot touches the plate. After 0.5 and 2 hours after treatment with the compound used in the experiment, the mice observe the first shock motion of one or both hind legs or until 10 seconds have passed without such movements. Morphine has MPEjp.4-5.6 mg / kg / s (subcutaneous administration).
    Analgesic experiments with mice hitting the tail.
    Each mouse is placed in an appropriate metal cylinder, so that the tail protrudes through one of the ends. The cylinder is positioned in such a way that the tail lies directly above the hidden heat lamp. When setting up the experiment, the aluminum flag that covers the lamp is pulled back, allowing the light beam to pass through the slit and focus on the tip of the tail. Simultaneously, the stopwatch is turned on. People who were not given medication usually react 3-4 seconds after the lamp has been exposed. The end point for treated animals is 10 s. Each experiment was performed 0.5 and 2 hours after taking morphine and the test compound. Morphine has an MPE of 3.2-5.6 mg / / kg (SC).
    Tail dip method.
    The method is an advanced receiver procedure proposed by Ben lassel et al. Male white mice (19-21 g) of the charles River CD-I breed are weighed and tagged for identification. Usually there are five animals in each group for drug treatment, each of which corresponds to a control animal. - For the purpose of general testing, new experienced agents are administered first at a dose of 56 mg / kg inside the peritoneum or by subcutaneous infusion in a volume of 10 ml / kg. Before taking the medicine and after 0.5 and 2 hours after it, each mass is placed in a cylinder. Each cylinder is provided with openings to provide adequate ventilation and is closed by a round nylon stopper through which the animal's tail is passed. The cylinder is held upright and the tail

    completely immersed in a water bath with a constant temperature of 56 ° C. The end point of each test is a vigorous, convulsive tail twitch in combination with a motor reaction. In some cases, after taking the medication, the reaction may be less strong. In order to prevent excessive tissue damage, the experiment is completed and the tail is removed from the bath after 10 s. The response hidden state is recorded in seconds with an accuracy of 0.5 s. The control carrier (without the drug) and the standard of known strength are tested simultaneously with screening candidates. Her1313
    If the activity of the test agent does not return to the established values during the 2-hour test, the reaction time is determined after 4 and 6 hours. The final measurements are carried out after 24 hours if the activity is still observed at the end of the experimental day.
    Experience using chemical nociceptive excitation.
    Suppression of twisting caused by a phenylbeisoquinone irritant.
    A group of 5 min. Carworth Farm CF-I is pretreated subcutaneously or orally with saline, morphine, codeine, or an experimental compound. Twenty minutes (if the treatment is subcutaneous) or fifty minutes (if the treatment is oral) after each group is treated with an intraperitoneal injection of phenyl benzoquinone, a known stimulant that causes boon-kip contractions. irritant It is established that pre-treatment with MPEjo medication blocks curling.
    Experiments using pressure as nociceptive excitation.
    The effect of Haffner by the method of pinching the tail - a modification of the method of the Haffner Experimentelle Prutung Schmer ztillender, Mittel Deutch - is used to establish the effects of the test compounds on an aggressive attack caused in response to the excitation by pinching of the tail.
    Male white rats (50 g) are used - the Charls River (Sprague-Dawley) CD breed. Before the treatment with the medicine and after 0.5, 1.2 and 3 hours after the treatment, clamp the bulldbg (Johns Hopkins 2.5 inches) and clamp the base
    7 MER. 13 1 2IZ P20: E 2 time - shutdown time - control time
    The compounds of formula I have been found to be particularly useful as anti-emetic and anti-nauseous agents for mammals to prevent vomiting and nausea caused by the administration of anti-neoplastic agents.
    The anti-emetic properties of the compounds of form I are determined on non-anesthesi-656314
    rat tail. The end point of each test is a clear aggressive behavior towards an irritant pathogen with a latency.
    5 notion of attack, expressed in seconds. The clip is removed after 30 seconds if the attack does not repeat and the latent reaction period is recorded as 30 seconds. Morphine has an activity of 17.8 mg / kg
    to (i.p.).
    Experiments using electrical nociceptive excitation. Experiments tearing-prmski. This is an improved technique.
    15 tearing - bouncing. Used to determine pain thresholds. Male white rats (175-200 g) of the breed Charles Rever (Sprague-Dawley) CD are used. Before receiving
    20 medicines each rat's paw is immersed in a 20% glycerol saline solution. The animals are then placed in a chamber and subjected to a sequence of 1 second strikes on the paw, which
    25 are conducted at a rate of 30 seconds. These are bits 0.26; 0.39; 0.52; 0.78; 1.05; 1.31; 1.58; 1.86; 2.13; 2.42; 2.72 and 3.04 mA. The behavior of each animal is judged by the presence of tearing, squeaking, bouncing, or fast movement during a shock attack.
    The sequence of blows with voz-. 35, each rat receives an increasing intensity immediately before and after 0.5; 2.4 and 24 hours after taking the medicine.
    The results of the above experiments are recorded as a percentage of the maximum possible effect (% MPE). The% MVE of each group is statistically compared with the% MVE of the standard and the reference value before administration. 45 medications. The% MPE is calculated as follows:
    Bathing cats according to well-known methods.
    Antagonism of PGE (prostaglandin E). Diarrhea in mice.
    The inhibitory activity of the compounds of Formula I is determined by the improved method of Dajani et al. European Jour. Pharmacol., 34,
    151
    105-113, 1975. This is a method for reliably detecting diarrhea in untreated mice for 15 minutes. Animals that do not have diarrhea prior to treatment are considered protected. Shut-off effects are measured as an all or nothing response, with diarrhea being defined as loose stools, very different from the normal fecal matter, which consists of well-formed, strong and relatively dry balls.
    Use white mice, males, breed Charles River CD-K
    They are placed in groups in cages and, starting from this point on, the experiments are carried out for one week, the Weight of animals during the experiments of 20-25 g. Tableted rat food is delivered in plenty. After 18 hours, the food was removed.
    Animals are weighed and labeled for identification. Usually, up to five animals in each group are treated with the drug. Mice weighing 20–25 g are placed in groups in cages and kept hungry during the night before the experiment. Water give plenty. Animals are given PGE about 32 mg / kg (ip) in 5% ethanol one hour after taking the medicine and immediately placed separately in transparent acrylic drawers measuring 15 x 18 cm. One-time use of a cardboard sheet on the bottom of the screen. they are treated for diarrhea after 15 min. The group treated with solvent + PGE, and the group treated with solvent, serve as a control.
    The data are analyzed using weight linear regression using the maximum probability method. The computer program prints the results of a linear regression format analysis, including degrees of freedom, sum of squares, rms and critical values, and psi / Chi square. If the regression is significant, E0, EDso,, EDgoH, then the 95% range is calculated.
    Compounds of formula I are active analgesic, antidote, antiemetic, and anti-6316
    nauseous compounds administered orally or parenterally in the form of a composition. The compositions include a pharmaceutical carrier selected depending on the method of administration and the usual pharmaceutical practice, for example, they can be administered in the form of tablets, pills, powders or granules containing ta-7
    cue excipients like starch, milk sugar, certain types of clays, etc. They can be administered in capsules, mixtures, with the same or equivalent excipients, or in the form of an oral suspension, solutions, emulsions, syrups and elixirs, which may contain flavor and color. general agents. For oral administration of therapeutic agents of the formula
    tablets or capsules containing from about 0.01 to. about 100 mg are suitable for most applications. I
    Suspensions and solutions of these drugs
    usually prepared immediately prior to use in order to avoid their instability (oxidation or precipitation) during
    storage. For this purpose, mainly dry solid compositions are used, which are reconstructed for injection purposes.
    Doctors determine the dose that is most appropriate for the patient in each case. It varies according to age, weight, and depends on the characteristics of the patient’s body and the method of administration. Typically, the initial anesthetic dose as well as the initial dose for preventing or treating nausea for adults is 0.0) -5 00 kg per day in single or divided doses. In many cases, there is no need to exceed a daily dose of 100 mg. A suitable oral dose is 0.01-50, parenteral 0.01-100 mg per day, preferably 0.01-20 mg per day.
    The results of screening anesthetics and protivoponnogo tests of compounds of formula I are given in table. 2
    17
    M o
    1316563
    .18
    table 2
    Q Q,
    SNZ M ZW
    one
    about YAOO 10 10 100 .10
    ten
    100 10 10 100 10
    100 10 10 100 10
    10 100 10 10 100 10 10 10-10
    7.3 0.22 0.08 0.21. 0.07
    nineteen
    Note. A- ONSSN,).
    B - C (CH,) ,, (CH) 5CH ,;
    C - CH2CH (CH,) j;
    PBQ - phenylbenzoquinone; .
    PQEj - prostaglandin antagonism
    MTF - tail pinching technique.
    Example 13. d-1 -5-OXI-4- (2-hydroxyethyl) -2,2-dimethyl-7- (1,1-di-methylmethyl) -3,4-dihydro-2H-benzopyran ( 100 mg) is uniformly mixed and dissolved with 900 ml of starch. The mixture is then loaded into telescopic gelatin capsules so that each capsule contains 10 mg of the drug and 90 mg of starch.
    1316563
    20 Continued table. 2
    Example 14 (24). The basis of the tablets prepared by mixing the following ingredients, h:
    Sucrose 80.3
    Cassava starch13, 2
    Magnesium stearate 6.5 Sufficient amount of d-l-5-aceticoxy-4- (2-acetylaminoethyl) -2,2-dime2113
    Tyl-7- (1,1-dimethylheptyl) -3,4-dihydro-2H-benzopyran is mixed with this base to make tablets containing 0.1; 0.5; 1.5; 10 and 25 mg of medication
    P p and m. 8 p 15 (25). A suspension of d-1-5-hydroxy-3- (3-hydroxypropyl) -2,2-di-methyl-7- (5-phenyl-2-pentyloxy) -3,4-dihydro-2H-benzopyran is obtained by adding sufficient drug quantities to. 0.5% methycellulose to obtain suspensions containing 0.05 0.1; Oj5; 1.5 and 10 mg of drug per 1 ml.
    From the data table. 2, according to the flick of the tail, it follows that, when orally administered, the mice transfer the dosages of the proposed compounds from 7.3 to 320 mg / kg. The preferred dose for oral administration is 0.01-300 mg per day. This value corresponds to 0.0002-6.0 mg / kg per day for a person weighing 50 kg. Thus, the compounds provided are reasonably safe.
    The compounds of the formula I not only have a high level of activity as peripheral painkillers. Agents, they are rather selective because they have a very low level of action on the central nervous system and anesthetic activity comparable to that which is structurally similar.
    322
    The mouse tail shake (MTF) test is a well-known test for measuring the activity of agents towards the central nervous system.
    the system. The test for determining irritation and convulsions caused by phenybenzoquinone is a measure of the peripheral analgesic effects.
    As a measure of selective peripheral analgesic effect, the MPEjg ratio is determined from the values obtained during the MTF and PBQ tests (MTF / PBQ). This ratio for compounds of formula I and known structurally similar compounds, characterized by formula V (described in US Pat. Nos. 4,143,139 () and No. 4,188,495 (M-CH., Cited
    in tab. 3-6:
    COQl
     OBi (I)
    n
    Zw bi
    cngm
    thirty
    in tab. Tables 3 and 4 describe compounds of Formula V (U.S. Patent No. 4,143,139) and Formula I, respectively, where.
    Beta-OH CH, CH, A
    Beta-OH CH, CH, C
    Betan-ON SI, CH, D
    Betan-ON N
    Morphine
    CH, E
    Table 3
    Ш 2-pyridsh1
    N 2-thiazolyl
    N-s
    : NHrV CH3
    O-n
    n
    NHCOCHCH,
    Characterization of Compounds of Formula V (US Patent No. 4,188,495) and ForBeta-OH H CH, CH, A3.3 0.78 4.2
    ONNINA1,6 0,32 5
    at 100 1010
    at 100 1010
     1010
    at 100 10
    ten
    7.3
    0.22
    33
    Mules I, where, is given in Tables 5 and 6.
    Table 5
    in tab. 3-6 A - (CH) CH2CHiCHjC5H; C (CH,) j (CH3) 5CH3; C - OCHCCHOCH CH CgHj; D - CH (CH,) CH (CH3) CyN ,,; E -, (CH, CH., CH2C5H).
    Based on the data presented in Table. 3-6, it can be concluded that the compounds of the formula I are characterized by significantly greater selectivity when used as peripheral anesthetic agents as compared to structurally similar compounds that are known and mentioned in U.S. Patent Nos. 4,143,139 and No. 4168495.
    Formula-invention
    The method of obtaining bicyclic benzo-condensed compounds of formula I
    Q OH
    SNS N ZW
    where M is an oxygen atom or CH ,,;
    Z is alkylene C4-C, or O (A1K,), where (A1K) is alkylene C, -C ,;
    . Q is a COQj group, where Q is a member selected from the group consisting of NHCOR ,, NHAr, NR, jR ,, NHOH, CHjCN, or CHjCOOC H, tityl;
    W is a hydrogen atom or phenyl;
    R and R is a hydrogen atom or C, -C alkyl;
    R, is a hydrogen atom, C-C alkyl, phenyl, benzyl, phenylethyl; Ag is selected from the group
    0
    .
    where R is a hydrogen atom or methyl.
    different unity of formula II
    the fact that COO-l-1502SbN5
    7.W
    is in contact with a compound of the formula HQ or MetQ, where Met. - Na, K or. Li, in an environment of a solvent at 20-157 ° C and the resulting intermediate compound of formula III debenzylates
    COQ
    OCH2SbN5
    five
    0
    five
    0
    five
    SNS
     Zw
    hydrogenolysis in the presence of a palladium catalyst in an organic solvent medium.
    Priority featured:
    03/16/82 when M is an oxygen atom or a CH2 group; Q is COQ, is a group, where Q is NRjR, where R and R, is a hydrogen atom or C —C-alkyl or HCORj, where R is a hydrogen atom, C, -; -alkyl or benzyl; Z is alkylene,; W is a hydrogen atom or phenyl.
    01/13/83 when M is an oxygen atom or a CH group; Q is a COQ group, where Q is NHOH, CHjCN, NHAr, NR2R3, NHCOR, where R, is a hydrogen atom, C, -C4-alksh1, phenyl, benzyl or phenylethyl; R and R, is a hydrogen atom or C, -C-alkyl; Ar - selected from group
    ov
    or
    5 G
    K Z is alkylene,; W is a hydrogen atom or phenyl.
    th
    about
    to
    权利要求:
    Claims (1)
    [1]
    The formula is as indicated in and No. 4168495.
    The method for producing bicyclic benzocondensed compounds of formula I is contacted with
    25. HQ or MetQ, where Met. - Na, K or. Li, in a solvent medium at 20-157 ° C, and the resulting intermediate of formula III is debenzylated
    COQ compound of the formula
    ZW oxygen or CH 2 ; or O (A1K ( ),) 9 ~ C 9 ;
    a COQ group ( where, is selected from the group consisting of NHCOR ( , NHAr, NR 2 R 3 , ΝΗΟΗ, CH 2 CN or CH 2 C00C 2 H5 ethyl;
    W is a hydrogen atom or phenyl;
    R t and R, - a hydrogen atom or C, -C 4 alkyl;
    R, phenyl, benzyl, phenylethyl; Ar from the group where M is an atom
    Z is alkylene C 4 -C 9 where (A1K) is alkylene C
    Q member hydrogen atom, C, -C 9 -alkyl, selected
    O 'ift - sO
    NO s where R 4 is a hydrogen atom or methyl, characterized in that the compound of formula II or CH 2 group; Q 45 by hydrogenolysis in the presence of a palladium catalyst in an organic solvent medium.
    Priority featured:
    03.16.82 at M - oxygen atom COQ ( -group, where
    Q is NR 2 R 9 where Rj and R are a hydrogen atom or C t -C 4 -alkyl or HCOfy, where R is a hydrogen atom, benzyl; Z is hydrogen alkylene or phenyl.
    01/13/83 at M or CH g group; QQ is NHOH, CH 2 CN, where R is a hydrogen atom, phenyl, benzyl or phenylethyl; R is a hydrogen atom or C, -C ^ alkyl; selected from
    C <-C 4 -alkyl or C <-C 9 ; W - atom oxygen atom
    COQ group, where NHAr, NR 2 R 3 , NHCOR,
    C | -C 4 -alkyl, g and R s groups
    类似技术:
    公开号 | 公开日 | 专利标题
    KR100430022B1|2004-07-16|Compounds Active at a Novel Site on Receptor-Operated Calcium Channels Useful for Treatment of Neurological Disorders
    RU2167152C2|2001-05-20|N-substituted azaheterocyclic carboxylic acids or their pharmaceutically acceptable salts, method of their synthesis, pharmaceutical composition based on thereof and method of inhibition of neurogenic inflammation
    TW200400186A|2004-01-01|-4-Amino-5-chloro-2-methoxy-N-[1-[1-[2-tetrahydrofuryl-carbonyl]-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof , pharmaceutical composition containing the same , and intermediate therefor
    US8063060B2|2011-11-22|R|-11-hydroxyaporphine derivatives and uses thereof
    DK160501B|1991-03-18|SUBSTITUTED BENZO TESTERS OF 3-HYDROXYMORPHINANES AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH SUGAR
    DE2609645A1|1977-09-15|AMINOALKYLHETEROCYCLES
    SU1316563A3|1987-06-07|Method for producing dicyclic benzocondensed compounds
    SU1217254A3|1986-03-07|Method of producing derivatives of 9-amino-1-oxyoctahydrobenzo|quinole or their salts which are acceptable in pharmacy
    ES2283122T3|2007-10-16|PROCEDURES AND COMPOSITIONS FOR THE TREATMENT OF DEPRESSION.
    JP2004535413A|2004-11-25|Cinnamide derivatives as KCNQ potassium channel modulators
    US4139634A|1979-02-13|Indole derivatives and process for preparing the same
    AU668863B2|1996-05-23|Arylmorpholine, preparation and use
    US5250537A|1993-10-05|5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole,-6,7,8,9,10-hexahydro-7,11-imino-5H-cyclooct[b]indole and substituted derivatives
    FR2534921A1|1984-04-27|HETEROCYCLIC AMINO COMPOUNDS AND PROCESSES FOR THEIR PREPARATION
    JPH06293761A|1994-10-21|Spiro-crosslinking and noncrosslinking heterocyclic compound
    WO2002092592A1|2002-11-21|Novel 1-amidomethylcarbonyl-piperidine derivatives, method and intermediate products for the production thereof and medicament containing said compounds
    GB2120244A|1983-11-30|Aminoalkadiene derivative
    CN109476696A|2019-03-15|Animal and the anti-trypanosome of people and anti-Leishmania agent
    US3248292A|1966-04-26|Pharmaceutically active dimethoxyquinazolines
    EA012283B1|2009-08-28|New naphthalene derivatives, method of preparing same and pharmaceutical composition containing them
    SU1217248A3|1986-03-07|Method of producing derivatives of 4-|phenylnaphthalene-2-oles
    US4173636A|1979-11-06|Decahydroquinolines, pharmaceutical compositions and methods of use
    Humber et al.1978|Neuroleptics related to butaclamol. An investigation of the effects of chlorine substituents on the aromatic rings
    AU598644B2|1990-06-28|Compounds and treatment
    EP0256181A1|1988-02-24|Novel quinaldinamide derivatives and their preparations
    同族专利:
    公开号 | 公开日
    ES8404344A1|1984-04-16|
    FI830858L|1983-09-17|
    NO167388B|1991-07-22|
    FI830858A0|1983-03-15|
    IE830558L|1983-09-16|
    AU1244783A|1983-10-06|
    FI80026C|1990-04-10|
    US4486428A|1984-12-04|
    ES527119A0|1985-05-01|
    NO830901L|1983-09-19|
    YU158585A|1986-04-30|
    PH20023A|1986-09-01|
    FI80026B|1989-12-29|
    YU43171B|1989-04-30|
    KR840004098A|1984-10-06|
    PT76391B|1986-02-03|
    DE3381782D1|1990-09-13|
    EP0089781A3|1985-08-14|
    EP0089781A2|1983-09-28|
    JPS58180456A|1983-10-21|
    AU540001B2|1984-10-25|
    CA1215984A|1986-12-30|
    KR870001281B1|1987-06-30|
    DD211559A5|1984-07-18|
    HU196983B|1989-02-28|
    EG16139A|1986-12-30|
    GR77126B|1984-09-07|
    PT76391A|1983-04-01|
    DK85683D0|1983-02-24|
    NZ203579A|1986-11-12|
    IL68117D0|1983-06-15|
    ES520631A0|1984-04-16|
    DD219764A5|1985-03-13|
    DK85683A|1983-10-05|
    IE55991B1|1991-03-13|
    EP0089781B1|1990-08-08|
    NO167388C|1991-10-30|
    YU44524B|1990-08-31|
    ES8504759A1|1985-05-01|
    YU63183A|1986-04-30|
    IL68117A|1986-03-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3636058A|1966-03-25|1972-01-18|Hoffmann La Roche|7 10 - dihydro - 3 - alkyl - 6h - dibenzo pyran-6 9-diones and 5-hydroxy-7-alkyl-4-chromanones|
    JPS49116069A|1972-10-24|1974-11-06|
    GB1470493A|1975-08-12|1977-04-14|Beecham Group Ltd|Anti-hypertensive 4-1-2-naphthyl-methyl-1,2,5,6-tetrahydro pyrid-4-yl-chroman-5-ol esters|
    GB1522057A|1975-11-03|1978-08-23|Pfizer|9-hydroxydibenzopyrans and intermediates therefor|
    US4087545A|1976-02-17|1978-05-02|Eli Lilly And Company|Hexahydro-dibenzo[b,d]pyran-9-ones as antiemetic drugs|
    US4260764A|1976-12-22|1981-04-07|Pfizer Inc.|9-Hydroxyoctahydrobenzo [C] quinolines and intermediates therefor|
    US4235913A|1977-06-07|1980-11-25|Pfizer Inc.|9-Hydroxyhexahydrodibeno[b,d]pyrans, 1-substituted-9-hydroxyhexahydrodibenzo]b,d]pyrans|
    US4188495A|1977-11-14|1980-02-12|Pfizer Inc.|1,9-Dihydroxyoctahydrophenanthrenes and intermediates therefor|
    US4152450A|1978-02-17|1979-05-01|Eli Lilly And Company|9-Amino-dibenzopyrans|
    US4210663A|1978-11-08|1980-07-01|Pfizer Inc.|Halogen substituted benzopyran- and benzothiopyran-4-carboxylic acids|
    US4181729A|1979-03-21|1980-01-01|Pfizer Inc.|Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives|
    US4228169A|1979-06-26|1980-10-14|Pfizer Inc.|1,9-Dihydroxyoctahydrobenzo[c]quinolines and 1-hydroxyhexahydrobenzo[c]quinoline-9-ones as antiemetic agents|
    EP0065392B1|1981-05-13|1985-02-13|Imperial Chemical Industries Plc|Pharmaceutical compositions containing spiro succinimide derivatives|WO1987004344A1|1986-01-17|1987-07-30|Pfizer Inc.|Hydroxyacetic acid derivatives for the treatment of diabetic complications|
    US4943428A|1987-07-10|1990-07-24|Wright State University|Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents|
    AU628331B2|1988-05-06|1992-09-17|Merck Patent Gesellschaft Mit Beschrankter Haftung|Chroman derivatives|
    DE3837809A1|1988-11-08|1990-05-10|Merck Patent Gmbh|tetralin|
    GB8911280D0|1989-05-17|1989-07-05|Beecham Group Plc|Novel compounds|
    DE3924417A1|1989-07-24|1991-01-31|Merck Patent Gmbh|chroman|
    US5155130A|1989-08-11|1992-10-13|Ciba-Geigy Corporation|Certain benzopyran and benzothiopyran derivatives|
    US5120758A|1991-02-08|1992-06-09|Ciba-Geigy Corporation|Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US35875182A| true| 1982-03-16|1982-03-16|
    US06/457,171|US4486428A|1982-03-16|1983-01-13|Bicyclic benzo fused compounds|
    [返回顶部]